1-Methyl-1,2,3,4-Tetrahydroisoquinoline, an endogenous amine with unexpected mechanism of action: New vistas of therapeutic application

Neurotoxicity Research

Volumn 25, Issue 1, 2014, Pages 1-12

  Antkiewicz Michaluk, Lucyna ^a   Wąsik, Agnieszka ^a   Michaluk, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1MeTIQ; Addiction; Brain dopamine metabolism; Neuroprotection; Rat; TIQ

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; MORPHINE; ROTENONE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; 1,2,3,4-TETRAHYDROISOQUINOLINE; 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE; AMINE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ANTIADDICTIVE ACTIVITY; ANTICONVULSANT ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; BEHAVIOR; BRAIN; BRAIN FUNCTION; COCAINE DEPENDENCE; DEGENERATIVE DISEASE; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; FRONTAL CORTEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDIAL FOREBRAIN BUNDLE; MOLECULAR BIOLOGY; MORPHINE ADDICTION; NEUROCHEMISTRY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SUBSTANCE ABUSE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME; ANIMAL; BRAIN LEVEL; COCAINE-RELATED DISORDERS; MORPHINE DEPENDENCE; RAT;

RATTUS; RODENTIA;

AMINES; ANIMALS; BRAIN CHEMISTRY; COCAINE-RELATED DISORDERS; DOPAMINE ANTAGONISTS; HUMANS; MORPHINE DEPENDENCE; NEUROPROTECTIVE AGENTS; RATS; TETRAHYDROISOQUINOLINES;

EID: 84891849731     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9402-7     Document Type: Review

References (143)

1. Abe K, Taguchi K, Wasai T, Ren J, Utsunomiya I, Shinohara T, Miyatake T, Santo T (2001) Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4- tetrahydroisoquinolines on a mouse model of Parkinson's disease. Brain Res Bull 56:55-60 (Pubitemid 32962939)
2. Absi E, Parrado J, Ayala A, Machado A (2002) Decrease of 1-methyl-1,2,3,4-tetrahydroisoquinoline synthesizing enzyme activity in the brain areas of aged rat. Brain Res 955:161-163 (Pubitemid 35284845)
3. Antkiewicz-Michaluk L, Vetulani J (2001) Tetrahydroisoquinolines as endogenous neurotoxins and neuroprotectants. Acta Neurobiol Exp 61:246
4. Antkiewicz-Michaluk L, Michaluk J, Romanska I, Papla I, Vetulani J (2000a) Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm 107:1009-1019
5. Antkiewicz-Michaluk L, Romanska I, Papla I, Michaluk J et al (2000b) Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain. Neuroscience 96:59-64 (Pubitemid 30103603)
6. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romanska I, Lorenc-Koci E, Ohta S, Vetulani J (2001) Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 78:100-108 (Pubitemid 32622592)
7. Antkiewicz-Michaluk L, Karolewicz B, Romanska I, Michaluk J, Bojarski A, Vetulani J (2003) 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 466:263-269 (Pubitemid 36412089)
8. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romanska I, Bojarski A, Vetulani J (2004) Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7:155-163 (Pubitemid 38823282)
9. Antkiewicz-Michaluk L, Filip M, Kostowski W, Patsenka A et al (2005) 1-Methyl-1,2,3,4-tetrahydroisoquinoline attenuates ethanol, cocaine and morphine addiction in behavioral models: neurochemical correlates. Acta Neurobiol Exp 65:301-321
10. Antkiewicz-Michaluk L, Lazarewicz JW, Patsenka A, Kajta M, Zieminska E, Salinska E, Wasik A, Golembiowska K, Vetulani J (2006) The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 97:846-856
11. Antkiewicz-Michaluk L, Filip M, Michaluk J, Romanska I et al (2007) An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 114:307-317 (Pubitemid 46328651)
12. Antkiewicz-Michaluk L, Wasik A, Romanska I, Bojarski A, Michaluk J (2011) Both stereoselective (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release. Neurotox Res 20:134-149
13. Ayala A, Parrado J, Cano J, Machado A (1994) Reduction of 1-methyl 1,2,3,4-tetrahydroisoquinoline level in substantia nigra of the aged rat. Brain Res 638:334-336 (Pubitemid 24063322)
14. Baker DA, Nguyen LTL, Fuchs RA, Neisewander JL (2001) Influence of individual differences and chronic fluoxetine treatment on cocaine-seeking behavior in rats. Psychopharmacology 155:18-26 (Pubitemid 32295765)
15. Berger SP, Hall S, Mickalian JD, Reid MS et al (1996) Haloperidol antagonism of cue-elicited cocaine craving. Lancet 347:504-508 (Pubitemid 26061611)
16. Berridge K, Robinson T (1998) What is the role dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 28:309-369 (Pubitemid 29012677)
17. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306
18. Campiani G, Butini S, Trotta F, Fattorusso C et al (2003) Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 46:3822-3839 (Pubitemid 37034135)
19. Carroll FI, Runyon SP, Abraham P et al (2004) Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. J Med Chem 47:6401-6409 (Pubitemid 39587263)
20. Chapman D, Way E (1982) Modification of endorphin/enkephalin analgesia by divalent cations, a cation chelator and ionophore. Br J Pharmacol 75:389-396 (Pubitemid 12213568)
21. Collins MA, Bigdeli MG (1975) Tetrahydroisoquinolines in vivo. I. Rat brain formation of salsolinol, a condensation product of dopamine and acetaldehyde, under certain conditions during ethanol intoxication. Life Sci 16:585-601
22. Collins MA, Nijm WP, Borge GF, Teas G et al (1979) Dopamine-related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption. Science 206:1184-1186 (Pubitemid 10159656)
23. Contreras E, Tamayo L, Amigo M (1988) Calcium channel antagonists increase morphine-induced analgesia and antagonize morphine tolerance. Eur J Pharmacol 148:463-466
24. Cornish JL, Duffy P, Kalivas PW (1999) A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience 93:1359-1367 (Pubitemid 29397564)
25. Davis VE, Walsh MJ (1970) Alcohol, amines, and alkaloids: a possible biochemical basis for alcohol addiction. Science 167:1005-1007
26. Del Pozo E, Caro G, Baeyens EM (1987) Analgesic effects of several calcium channel blockers in mice. Eur J Pharmacol 137:155-160 (Pubitemid 17098042)
27. Di Chiara G (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95-137
28. Di Chiara G (2002) Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 137:75-114 (Pubitemid 35346430)
29. Di Chiara G, Bassareo V, Fenu S, De Luca MA et al (2004) Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47:227-241 (Pubitemid 39298267)
30. Di Ciano P, Coury A, Depoortere RY, Egilmez Y et al (1995) Comparison of changes in extracellular dopamine concentrations in the nucleus accumbens during intravenous self-administration of cocaine or d-amphetamine. Behav Pharmacol 6:311-322
31. Dykens JA (1999) Free radicals and mitochondria dysfunction in excitotoxicity and neurodegenerative disease. In: Koliatsos VE, Ratan RR (eds) Death and diseases of the nervous system. Humana Press, Totowa
32. Fallon JH, Loughlin SE (1995) Substantia nigra. In: Paxinos G (ed) The rat nervous system. Academic Press, San Diego
33. Ferreri G, Chimirri A, Russo E, Gitto R, Gareri P, De Sarro A, De Sarro G (2004) Comparative anticonvulsant activity of N-acetyl-1-aryl-6-7-dimethoxy-1, 2,3,4-tetrahydroisoquinoline derivatives in rodents. Pharmacol Biochem Behav 77:85-94 (Pubitemid 38076984)
34. Filip M, Antkiewicz-Michaluk L, Zaniewska M, Frankowska M, Golda A, Vetulani J, Przegalinski E (2007) Effects of 1-methyl-1,2,3,4- tetrahydroisoquinoline on the behavioral effects of cocaine in rats. J Physiol Pharamacol 58:625-639
35. Fuchs RA, Tran-Nguyen LTL, Specio SE, Groff RS et al (1998) Predictive validity of the extinction/reinstatement model of drug craving. Psychopharmacology 135:151-160 (Pubitemid 28055498)
36. Garzon J, Fuentes J, Del Rio J (1979) Effect of selective monoamine oxidase inhibitor drugs on morphine tolerance and physical dependence in mice. Neuropharmacology 18:531-536 (Pubitemid 9195701)
37. Gawin FH (1991) Cocaine addiction: psychology and neurophysiology. Science 251:1580-1586 (Pubitemid 21916925)
38. Ginos JZ, Doroski D (1979) Dopaminergic antagonists: effects of 1,2,3,4-tetrahydroisoquinoline and its N-methyl and N-propyl homologs on apomorphine- and l-dopa-induced behavioral effects in rodents. J Pharmacol Exp Ther 209:79-86 (Pubitemid 9191976)
39. Gitto R, Barreca ML, De Luca L, De Sarro G, Ferreri G, Quartarone S, Russo E, Constanti A, Chimirri A (2003) Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist. J Med Chem 46:197-200 (Pubitemid 36043801)
40. Goldstein RZ, Volkov ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642-1652
41. Grassing K, He S (2005) Effects of high-dose of selegiline on morphine reinforcement and precipitated withdrawal in dependent rats. Behav Pharmacol 16:1-13 (Pubitemid 40354361)
42. Gratton A, Wise RA (1994) Drug- and behavior-associated changes in dopamine-related electrochemical signals during intravenous cocaine self-administration in rats. J Neurosci 14:4130-4146 (Pubitemid 24200538)
43. Greenamyre JT, Betarbet R, Sherer T, Panov A (2001) Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24:247 (Pubitemid 32304460)
44. Grimm JW, Lu L, Hayashi T, Hope BT et al (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 23:742-747 (Pubitemid 36206164)
45. Gutman M, Singer TP, Beinert H, Casida JE (1970) Reaction sites of rotenone, piericidin A, and amytal in relation to the nonheme iron components of NADH dehydrogenase. Proc Natl Acad Sci USA 65:763-770
46. Harman D (1981) The aging process. Proc Natl Acad Sci USA 78:7124-7128
47. Heidbreder CA, Hagan JJ (2005) Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Curr Opin Pharmacol 51:107-118 (Pubitemid 40124543)
48. Horgan DJ, Singer TP, Casida JE (1968) Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. 13. Binding sites of rotenone, piericidin A, and amytal in the respiratory chain. J Biol Chem 243:834-843
49. Igarashi K, Sugiyama Y, Kasuya F, Saiki K, Yamakawa T, Ohta S (1999) Determination of 1-methyl-1,2,3,4-tetrahydroisoquinoline in mouse brain after treatment with haloperidol by gas chromatography-selected ion monitoring. J Chromatogr B Biomed Sci Appl 731:53-58 (Pubitemid 29376413)
50. Inglis FM, Moghaddam B (1999) Dopaminergic innervation of the amygdala is highly responsive to stress. J Neurochem 72:1088-1094 (Pubitemid 29085023)
51. Inoue H, Matsubara D, Tsuruta Y (2008) Simultaneous analysis of 1,2,3,4-tetrahydroisoquinolines by high-performance liquid chromatography using 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride as a fluorescent labeling reagent. J Chromatogr B Anal Technol Biomed Life Sci 867:32-36
52. Ishiwata K, Koyanagi Y, Saitoh T, Taguchi K, Toda J, Sano T, Senda M (2001) Effects of single and repeated administration of 1,2,3,4- tetrahydroisoquinoline analogs on the binding of (11C)raclopride to dopamine D2 receptors in the mouse brain. J Neural Transm 108:1111-1125 (Pubitemid 33022761)
53. Ito R, Dalley JW, Robbins TW, Everitt BJ (2002) Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. J Neurosci 22:6247-6253 (Pubitemid 35387665)
54. Jenner P (2001) Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24:245-247
55. Jenner P, Marsden CD (1986) The action of 1-methyl-4-phenyl-1,2,3,4- tetrahydropyridine in animals as a model of Parkinson's disease. J Neural Transm Suppl 20:11-39
56. Kalivas PW (1995) Interaction between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend 37:95-100
57. Kalivas PW, McFarland K (2003) Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 168:44-56 (Pubitemid 36851162)
58. Kalivas PW, Volkow N, Seamans J (2005) Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45:647-650 (Pubitemid 40320699)
59. Kamikubo K, Niwa M, Fugimura H, Miura K (1983) Morphine inhibits depolarization-dependent calcium uptake by synaptosomes. Eur J Pharmacol 95:149-150 (Pubitemid 14248287)
60. Karoum F, Suddath RL, Wyatt RJ (1990) Chronic cocaine and rat brain catecholamines: long-term redaction in hypothalamic and frontal cortex dopamine metabolism. Eur J Pharmacol 186:1-8 (Pubitemid 20277540)
61. Kelley AE (2004a) Memory and addiction: shared neuronal circuitry and molecular mechanisms. Neuron 44:161-179 (Pubitemid 39348838)
62. Kelley AE (2004b) Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci Biobehav Rev 27:765-776 (Pubitemid 38202248)
63. Khanna NC, Sharma SK (1983) Megadoses of vitamin C prevent the development of tolerance and physical dependence on morphine in mice. Life Sci 33:401-404 (Pubitemid 14249972)
64. Kohno M, Ohta S, Hirobe M (1986) Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Commun 140:448-454 (Pubitemid 17190044)
65. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M (1995) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65:2633-2638
66. Kotake Y, Taguchi R, Okuda K, Sekiya Y, Tasaki Y, Hirobe M, Ohta S (2005) Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res 1033:143-150 (Pubitemid 40193408)
67. Kuszczyk M, Slomka M, Antkiewicz-Michaluk L, Salinska E et al (2010) 1-Methyl-1,2,3,4-tetrahydroisoquinoline and established noncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity. Pharmacol Rep 62:1041-1050
68. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980 (Pubitemid 13189531)
69. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451 (Pubitemid 30164887)
70. Le Foll B, Goldberg SR, Sokoloff P (2005) The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525-541 (Pubitemid 41169976)
71. Lima MS, Reisser AA, Soares BG, Farrell M (2003) Antidepressants for cocaine dependence. Cochrane Database of Systematic Reviews 2 CD002950. doi: 10.1002/14651858
72. Little KY, Patel UN, Clark TB, Butts JD (1996) Alteration of brain dopamine and serotonin levels in cocaine users: a preliminary report. Am J Psychiatry 153:1216-1218 (Pubitemid 26299845)
73. Locke KW, Levesque TR, Nicholson KL, Balster RL (1996) Dexfenfluramine lacks amphetamine-like abuse potential. Prog Neuropsychopharmacol Biol Psychiatry 20:1019-1035 (Pubitemid 26300470)
74. Lorenc-Koci E, Wojcikowski J, Kot M, Haduch A et al (2004) Disposition of 1,2,3,4-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats. Brain Res 996:168-179 (Pubitemid 38022013)
75. Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ (2006) 1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology 50:133-142 (Pubitemid 43099999)
76. Ma YY, Guo CY, Yu P, Lee DY et al (2006) The role of NR2B containing NMDA receptor in place preference conditioned with morphine and natural reinforcers in rats. Exp Neurol 200:343-355 (Pubitemid 44131532)
77. Mach UR, Hackling AE, Perachon S, Ferry S et al (2004) Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands. Chem Biochem 5:508-518 (Pubitemid 39257108)
78. Makino Y, Ohta S, Tachikawa O, Hirobe M (1988) Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson's disease. Life Sci 43:373-378
79. Makino Y, Tasaki Y, Ohta S, Hirobe M (1990) Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. Biomed Environ Mass Spectrom 19:415-419 (Pubitemid 20335928)
80. Marey-Semper I, Gelman M, Levi-Strauss M (1993) The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 5:1029-1034 (Pubitemid 23239788)
81. Matsubara K, Fukushima S, Akane A, Kobayashi S et al (1992) Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing l-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from l-3,4-dihydroxyphenylalanine in humans. J Pharmacol Exp Ther 260:974-988
82. McNaught KS, Carrupt PA, Altomare C, Cellamare S et al (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 56:921-933 (Pubitemid 28454556)
83. 2+ channel antagonists on morphine analgesia, tolerance and dependence, and on blood pressure in the rat. Eur J Pharmacol 352:189-197 (Pubitemid 28345117)
84. Michaluk J, Krygowska-Wajs A, Karolewicz B, Antkiewicz-Michaluk L (2002) Role of noradrenergic system in the mechanism of action of endogenous neurotoxin 1,2,3,4-tetrahydroisoquinoline: biochemical and functional studies. Pol J Pharmacol 54:19-25 (Pubitemid 34269619)
85. Mogenson GJ, Jones DL, Yim CY (1980) From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 14:69-97 (Pubitemid 10053405)
86. Moore RJ, Vinsant SL, Nader MA, Porrino LJ et al (1998a) Effect of cocaine self-administration on striatal dopamine D1 receptors in rhesus monkeys. Synapse 28:1-9 (Pubitemid 128770597)
87. Moore RJ, Vinsant SL, Nader MA, Porrino LJ et al (1998b) Effect of cocaine self-administration on striatal dopamine D2 receptors in rhesus monkeys. Synapse 30:88-96 (Pubitemid 28361187)
88. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 29:99-111 (Pubitemid 27422504)
89. Nagy J (2004) The NR2B subtype of NMDA receptor: a potential target for the treatment of alcohol dependence. Curr Drug Targets CNS Neurol Disord 3:169-179 (Pubitemid 38854912)
90. Naoi M, Maruyama W (1993) Type B monoamine oxidase and neurotoxins. Eur Neurol 33:31-37 (Pubitemid 23235374)
91. Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotoxicology 25:193-204 (Pubitemid 38044181)
92. Narayanan S, Willins D, Dalia A, Wallace L, Uretsky N (1996) Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav 54:565-573 (Pubitemid 26180197)
93. Nicholson KL, Balster RL (2003) Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats. Psychopharmacology 170:215-224 (Pubitemid 37421534)
94. Niwa T, Takeda N, Kaneda N, Hashizume Y, Nagatsu T (1987) Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroisoquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun 144:1084-1089 (Pubitemid 17078794)
95. Niwa T, Yoshizumi H, Tatematsu A, Matsuura S, Nagatsu T (1989) Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J Chromatogr 493:347-352 (Pubitemid 19220073)
96. Niwa T, Yoshizumi H, Tatematsu A, Matsuura S, Yoshida M, Kawachi M, Naoi M, Nagatsu T (1990) Endogenous synthesis of N-methyl-1,2,3,4- tetrahydroisoquinoline, a precursor of N-methylisoquinolinium ion, in the brains of primates with parkinsonism after systemic administration of 1,2,3,4-tetrahydroisoquinoline. J Chromatogr 533:145-151
97. Ohta S, Kohno M, Makino Y, Tachikawa O, Hirobe M (1987) Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed Res 8:453-456
98. Ortwine DF, Malone TC, Bigge CF, Drummond JT, Humblet C, Johnson G, Pinter GW (1992) Generation of N-methyl-d-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl- substituted tetrahydroisoquinolines as novel antagonist. J Med Chem 35:1345-1370
99. Parsons LH, Koob GF, Weiss F (1995) Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Phramacol Exp Ther 274:1182-1191
100. Patsenka A, Antkiewicz-Michaluk L (2004) Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds - 1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol 56:727-734 (Pubitemid 40287474)
101. Perry TL, Jones K, Hansen S (1988) Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice. Neurosci Lett 85:101-104 (Pubitemid 18053447)
102. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25:192-216 (Pubitemid 27501800)
103. Pietraszek M, Michaluk J, Romanska I, Wasik A et al (2009) 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res 16:390-407
104. Pitkanen A (2000) Connectivity of the rat amygdaloid complex. In: Aggleton JP (ed) The amygdala. Oxford University Press, Oxford
105. Popik P, Mamczarz J, Fraczek M, Widla M et al (1998) Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology 37:1033-1042 (Pubitemid 28401492)
106. Pulvirenti L, Maldonado-Lopez R, Koob GF (1992) NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in rat. Brain Res 594:327-330
107. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223 (Pubitemid 17131228)
108. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18:247-291 (Pubitemid 23219500)
109. Rogawski MA, Thurkauf A, Yamaguchi S, Rice KC, Jacobson AE, Mattson MV (1989) Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetetrahydroquinoline. J Pharmacol Exp Ther 249:708-712 (Pubitemid 19166646)
110. Rommelspacher H, Susilo R (1985) Tetrahydroisoquinolines and β-carbolines: putative natural substances in plants and mammals. Prog Drug Res 29:415-459 (Pubitemid 16165832)
111. Rossetti ZL, Hmaidan Y, Gessa GL (1992) Marked inhibition of meso-limbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221:227-234
112. Sánchez-Blázquez P, Boronat BA, Olmos G, García-Sevilla JA et al (2000) Activation of 1(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 130:146-152 (Pubitemid 30248438)
113. Sandler M, Carter SB, Hunter KR, Stern GM (1973) Tetrahydroisoquinoline alkaloids: in vivo metabolites of l-dopa in man. Nature 241:439-443
114. Santiago M, Granero L, Machado A, Cano J (1995) Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur J Pharmacol 280:251-256
115. Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172-188 (Pubitemid 351219718)
116. Schultz W (2002) Getting formal with dopamine and reward. Neuron 36:241-263 (Pubitemid 35217890)
117. Schultz W (2010) Dopamine signals for reward value and risk: basic and recent data. Behav Brain Funct 6:24-38
118. Segal DS, Geyer MA, Schuckit MA (1981) Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol 5:95-129
119. Singer TP, Ramsay RR (1995) Flavoprotein structure and mechanism 2. Monoamine oxidases: old friends hold many surprises. FASEB J 9:605-610
120. Smelson DA, Williams J, Ziedonis D, Sussner BD et al (2004) A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat 27:45-49 (Pubitemid 38829778)
121. Sourkes TL (1971) Possible new metabolites mediating actions of l-dopa. Nature 229:413-414
122. Suzuki K, Mizuno Y, Yoshida M (1990) Effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-like compounds on mitochondrial respiration. Adv Neurol 53:215-218
123. Tasaki Y, Makino Y, Ohta S, Hirobe M (1991) 1-Methyl-1,2,3,4- tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem 57:1940-1943 (Pubitemid 21922843)
124. Tasaki Y, Makino Y, Ohta S, Hirobe M (1993) Biosynthesis of 1-methyl-1,2,3,4-tetrahydroisoquinoline (MeTIQ), a possible antiparkinsonism agent. Adv Neurol 60:231-233
125. Thiffault C, Langston JW, Di Monte DA (2000) Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 885:283-288
126. Thull U, Kneubühler S, Gaillard P, Carrupt PA, Testa B, Altomare C, Carotti A, Jenner P, McNaught KS (1995) Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. Biochem Pharmacol 50:869-877
127. 3H] spiroperidol binding in rat brain. Brain Res Bull 19:35-38 (Pubitemid 18037888)
128. Turner AJ, Baker KM, Algeri S, Erigerio A et al (1974) Tetrahydropapaveroline: formation in vivo and vitro in rat brain. Life Sci 14:2247-2257
129. Ungless MA (2004) Dopamine: the salient issue. Trends Neurosci 27:702-706 (Pubitemid 39488072)
130. Vanderschuren LJ, Kalivas PW (2000) Alteration in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151:99-120 (Pubitemid 30646415)
131. Vetulani J (2001) Drug addiction. Part II. Neurobiology of addiction (Review). Pol J Pharmacol 53:303-317
132. Vetulani J, Nalepa I, Antkiewicz-Michaluk L, Sansone M (2001) Opposite effect of simple tetrahydroisoquinolines on amphetamine- and morphine-stimulated locomotor activity in mice. J Neural Transm 108:513-526 (Pubitemid 32441868)
133. Vetulani J, Antkiewicz-Michaluk L, Michaluk J (2003a) Modification of morphine analgesia, tolerance and abstinence by 1,2,3,4-tetrahydroisoquinoline. Eur Neuropsychopharmacol 113:S29-S30
134. Vetulani J, Antkiewicz-Michaluk L, Nalepa I, Sansone M (2003b) A possible physiological role for cerebral tetrahydroisoquinolines. Neurotox Res 5:147-155
135. Wa̧sik A, Romanska I, Antkiewicz-Michaluk L (2007) The effect of an endogenous compound 1-methyl-1,2,3,4-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol 58:235-252 (Pubitemid 47026559)
136. Wa̧sik A, Romanska I, Ankiewicz-Michaluk L (2010) Important role of 3-methoxytyramine in the inhibition of cocaine sensitization by 1-methyl-1,2,3,4-tetrahydroisoquinoline: an in vivo microdialysis study. Pharmacol Rep 62:983-997
137. Wa̧sik A, Romańska I, Michaluk J, Antkiewicz-Michaluk L (2012) Comparative behavioral and neurochemical studies of R- and S-1-methyl-1,2,3,4-tetrahydroisoquinoline stereoisomers in the rat. Pharmacol Rep 64:857-869
138. Weiss F, Markou A, Lorang MT, Koob GF (1992) Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 593:314-318
139. Wilcox KM, Rowlett JK, Paul IA, Ordway GA et al (2000) On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology 153:139-147 (Pubitemid 32127912)
140. Yamakawa T, Ohta S (1997) Isolation of 1-methyl-1,2,3,4- tetrahydroisoquinoline-synthesizing enzyme from rat brain: a possible Parkinson's disease-preventing enzyme. Biochem Biophys Res Commun 236:676-681 (Pubitemid 27384688)
141. Yamakawa T, Ohta S (1999) Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci Lett 259:157-160 (Pubitemid 29059608)
142. Yamakawa T, Kotake Y, Fujitani M, Shintani H, Makino Y, Ohta S (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett 276:68-70 (Pubitemid 29525527)
143. Zarranz de Ysern ME, Ordoñez LA (1981) Tetrahydroisoquinolines: a review. Prog Neuropsychopharmacol 5:343-355 (Pubitemid 12213172)